AbbVie News
News
0
Ticker
ABBV
ISIN
US00287Y1091
AbbVie Stock News
AbbVie is being monitored by journalists and investors worldwide. We gather the latest AbbVie news here.
- September 15·Yahoo
- September 14·Yahoo
- September 14·Yahoo
- September 14·Yahoo
- September 14·Yahoo
- September 14·Yahoo
- September 14·Yahoo
- September 14·Yahoo
- September 14·Yahoo
- September 14·Yahoo
- September 12·Yahoo
- September 11·Yahoo
- September 11·Yahoo
- September 11·Yahoo
- September 11·Yahoo
- September 11·Yahoo
- September 11·Yahoo
- September 11·Benzinga
- September 11·Benzinga
- September 10·Yahoo
AbbVie Stock Press Releases
AbbVie regularly publishes news on the company's website that are relevant for investors.
- November 23•AbbVie
- November 23•AbbVie
- November 22•AbbVie
- November 22•AbbVie
- November 21•AbbVie
- November 17•AbbVie
- November 9•AbbVie
- November 8•AbbVie
- November 7•AbbVie
- November 3•AbbVie
- November 2•AbbVie
- October 28•AbbVie
- October 28•AbbVie
- October 24•AbbVie
- October 21•AbbVie
- October 20•AbbVie
- October 17•AbbVie
- October 7•AbbVie
- October 4•AbbVie
- September 29•AbbVie
- September 22•AbbVie
- September 19•AbbVie
- September 15•AbbVie
- September 14•AbbVie
- September 13•AbbVie
- September 10•AbbVie
- September 9•AbbVie
- September 8•AbbVie
- September 8•AbbVie
- September 7•AbbVie
AbbVie News 2026
This page contains all current news, analysis and press releases for AbbVie stock (ABBV, ISIN: US00287Y1091). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at AbbVie.
AbbVie Stock
AbbVie Abbvie Inc. is a global, research-oriented company specializing in the field of biotechnology and pharmaceuticals. It was founded in 2013 as a spin-off from Abbott Laboratories. Abbvie's headquarters are in North Chicago, Illinois, and it employs over 47,000 people in more than 75 countries worldwide. The company focuses on researching, developing, and marketing high-quality therapies for the treatment of serious and life-threatening diseases. Abbvie has several business divisions, including immunology, oncology, neurology, and virology, and is known for its investments in research and development. Its key products include adalimumab (sold under the brand name Humira) for autoimmune diseases and Imbruvica for chronic lymphocytic leukemia. Abbvie is recognized as a leading company in the biotechnology and pharmaceutical industry due to its focus on innovative therapies and medicines.